TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.

Wen-Zhao Zhong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.